Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Omeicos Therapeutics GmbH. (4/27/18). "Press Release: Alexander Gebauer Joins Executive Board of Omeicos Therapeutics and Named CEO and Chairman of Omeicos Ophthalmics". Berlin & Boston, MA.

Region Region United States (USA)
Organisation Organisation Omeicos Ophthalmics Inc.
  Group Omeicos (Group)
Products Product OMT-28 (Omeicos)
  Product 2 ophthalmic
Persons Person Gebauer, Alexander (Omeicos 201804– Executive Board Member + CEO of Omeicos Ophthalmics before Sun Pharma + Ranbaxy)
  Person 2 Fischer, Robert (Omeicos Therapeutics GmbH 201312 Managing Director (CSO))
     


-- Appointment marks further progress in ramping-up US-based subsidiary as validation of OMEICOS’ lead compound also progresses through clinical trials in atrial fibrillation --


OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of Alexander Gebauer, MD, Ph.D., to the Company’s Management Board. Dr. Gebauer will lead the clinical development efforts of OMEICOS Therapeutics GmbH. He has also been appointed to Chief Executive Officer and Chairman of the Board of the recently founded US-based subsidiary, OMEICOS Ophthalmics. Dr. Gebauer joins the OMEICOS leadership team with over 25 years of R&D experience within the biotechnology and pharmaceutical industry.

“Alexander’s impressive track record of accomplishments, most notably his success with leading regulatory organizations resulting in numerous approvals, provides OMEICOS with additional experienced leadership to mature our diverse pipeline,” said Robert Fischer, MD, CEO of OMEICOS Therapeutics. “As the development of our lead compound progresses through the clinic and our US subsidiary OMEICOS Ophthalmics accelerates its pace, adding breadth to the management team of OMEICOS is a crucial step in building the organization’s global footprint.”

“OMEICOS is entering a very exciting and promising phase of its corporate development. With Robert as CEO and today’s addition of Alexander as Managing Director we feel the OMEICOS team is very well positioned to progress its growing pipeline steadily towards its next value inflection point,” commented Dr. Bernd Kirschbaum, Chairman of the Board of OMEICOS.

In his role as Managing Director, Dr. Gebauer will oversee the clinical development of OMEICOS’ lead compound OMT-28 for rhythm control in patients with atrial fibrillation. Together with the team, he will steer the planning and clinical trial design for the upcoming Phase II trial in atrial fibrillation for which OMEICOS is currently raising additional capital. As Chief Executive Officer of OMEICOS Ophthalmics Inc., Dr. Gebauer is responsible for the advancement of OMEICOS’ drug discovery prospects in ophthalmology. This includes establishing further preclinical proof of concept with an external network of renowned experts in the field.

Dr. Gebauer commented, “OMEICOS has tremendous potential to make a fundamental change in the treatment of cardiovascular and ophthalmic diseases. I look forward to building on the company’s successes that have been achieved to date, capitalizing on expertise in the cardiology and ophthalmology fields which I gained in my previous roles.”

Prior to joining OMEICOS Therapeutics, Dr. Gebauer served in a multitude of R&D roles, including Managing Director, President of Global R&D, Chief Scientific Officer and other executive committee positions at several international pharmaceutical companies such as Sun Pharmaceuticals, Ranbaxy Laboratories Ltd., Merz Pharmaceuticals, Hoechst AG, Aventis and Sanofi. Dr. Gebauer studied medicine at Johann Gutenberg University, Mainz/Germany, where he completed his thesis in pharmacology.


About OMEICOS

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. OMEICOS’ technology is based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders, Dr. Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Mueller and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com


Contacts

OMEICOS Therapeutics GmbH
Dr. Robert Fischer, +49 (0) 30 9489 4810
CEO, CSO
r.fischer@omeicos.com
www.omeicos.com

or

Media:
MacDougall Biomedical Communications
Mario Brkulj or Kara Mazey
+49 89 2424 3494 or +1 781-235-3060
omeicos@macbiocom.com

   
Record changed: 2018-07-27

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Omeicos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top